RBC Capital Mkts slashes price target on Boston Scientific Corporation [BSX] – find out why.


Boston Scientific Corporation [NYSE: BSX] price surged by 0.71 percent to reach at $0.3. The company report on January 7, 2022 that Boston Scientific to Present New Data on Advances in Chronic Pain Care at the 2022 North American Neuromodulation Society (NANS) Meeting.

Boston Scientific Corporation (NYSE: BSX) today announced key data that will be featured at the 25th North American Neuromodulation Society (NANS) annual meeting, in Orlando, Florida, on Jan.13-15, 2022. More than 20 abstracts have been accepted, including three late-breaking presentations.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


The late-breaking presentation on the COMBO study, a randomized control trial, will highlight two-year outcomes demonstrating the durable effectiveness of the WaveWriter™ Spinal Cord Stimulator (SCS) System capable of delivering combination therapy – the ability to layer multiple waveforms and modalities simultaneously. Combination therapy is designed to offer more opportunities to customize SCS therapy and optimize outcomes.

A sum of 6367663 shares traded at recent session while its average daily volume was at 7.52M shares. Boston Scientific Corporation shares reached a high of $42.43 and dropped to a low of $41.44 until finishing in the latest session at $42.41.

The one-year BSX stock forecast points to a potential upside of 16.99. The average equity rating for BSX stock is currently 1.80, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on Boston Scientific Corporation [BSX]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BSX shares is $51.09 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BSX stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

RBC Capital Mkts have made an estimate for Boston Scientific Corporation shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on December 10, 2021. The new note on the price target was released on May 26, 2021, representing the official price target for Boston Scientific Corporation stock. Previously, the target price had yet another raise to $51, while Barclays analysts kept a Overweight rating on BSX stock.

The Average True Range (ATR) for Boston Scientific Corporation is set at 0.98, with the Price to Sales ratio for BSX stock in the period of the last 12 months amounting to 5.33. The Price to Book ratio for the last quarter was 3.67, with the Price to Cash per share for the same quarter was set at 1.35. Price to Free Cash Flow for BSX in the course of the last twelve months was 37.78 with Quick ratio for the last quarter at 1.20.

BSX Stock Performance Analysis:

Boston Scientific Corporation [BSX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.65. With this latest performance, BSX shares gained by 2.74% in over the last four-week period, additionally sinking by -1.51% over the last 6 months – not to mention a rise of 16.38% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BSX stock in for the last two-week period is set at 52.60, with the RSI for the last a single of trading hit 51.20, and the three-weeks RSI is set at 52.14 for Boston Scientific Corporation [BSX]. The present Moving Average for the last 50 days of trading for this stock 41.57, while it was recorded at 42.76 for the last single week of trading, and 42.72 for the last 200 days.

Insight into Boston Scientific Corporation Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Boston Scientific Corporation [BSX] shares currently have an operating margin of +6.06 and a Gross Margin at +56.25. Boston Scientific Corporation’s Net Margin is presently recorded at -0.83.

Return on Total Capital for BSX is now 2.44, given the latest momentum, and Return on Invested Capital for the company is -0.34. Return on Equity for this stock declined to -0.56, with Return on Assets sitting at -0.27. When it comes to the capital structure of this company, Boston Scientific Corporation [BSX] has a Total Debt to Total Equity ratio set at 62.73. Additionally, BSX Total Debt to Total Capital is recorded at 38.55, with Total Debt to Total Assets ending up at 31.24. Long-Term Debt to Equity for the company is recorded at 62.18, with the Long-Term Debt to Total Capital now at 38.21.

Reflecting on the efficiency of the workforce at the company, Boston Scientific Corporation [BSX] managed to generate an average of -$2,158 per employee. Receivables Turnover for the company is 5.72 with a Total Asset Turnover recorded at a value of 0.32.Boston Scientific Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.20 and a Current Ratio set at 1.50.


The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BSX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Boston Scientific Corporation go to 23.00%.

>> 7 Top Picks for the Post-Pandemic Economy <<

Boston Scientific Corporation [BSX] Insider Position Details

There are presently around $54,905 million, or 94.40% of BSX stock, in the hands of institutional investors. The top three institutional holders of BSX stocks are: BLACKROCK INC. with ownership of 122,400,261, which is approximately 3.868% of the company’s market cap and around 0.20% of the total institutional ownership; VANGUARD GROUP INC, holding 111,212,803 shares of the stock with an approximate value of $4.72 billion in BSX stocks shares; and FMR LLC, currently with $4.56 billion in BSX stock with ownership of nearly 4.156% of the company’s market capitalization.

Positions in Boston Scientific Corporation stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 413 institutional holders increased their position in Boston Scientific Corporation [NYSE:BSX] by around 67,852,135 shares. Additionally, 350 investors decreased positions by around 52,642,142 shares, while 159 investors held positions by with 1,174,120,152 shares. The mentioned changes placed institutional holdings at 1,294,614,429 shares, according to the latest SEC report filing. BSX stock had 77 new institutional investments in for a total of 13,465,730 shares, while 63 institutional investors sold positions of 5,368,154 shares during the same period.